Replies to post #233771 on Avid Bioservices Inc (CDMO)

[exwannabe]

MSK and now AZN are signing up the patients!

Where do you see that? The PPHM-AZN P1 will be run by PPHM:

Under the terms of the agreement, the initial trial will be conducted by Peregrine.

I will say that havng a BP in the game helps, but it still PPHM recruiting.

The MSK collab is less clear. But clearly starts out pre-clinical:

"A key focus of the Wolchok Lab's research is studying novel immunotherapy combinations that work together to enable the immune system to recognize and destroy cancer. This collaboration will allow us to focus on the role and contribution of PS blockade therapy in determining which combination of the current and next generation of immune modulators is likely to increase the extent and amplitude of anti-tumor response. This important pre-clinical and translational work will potentially guide the design of the next generation of clinical studies with bavituximab," said Dr. Merghoub.

The "translational" toss in is one of those ambiguous words. But even if it does mean a P1 to follow-up on the preclincal, I would seriously doubt MSK doses a single human before 2017.

[PPHMVERYLONG]

Fully enroll.